Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

[ 223 Ra] RaCl 2 nanomicelles showed potent effect against osteosarcoma: targeted alpha therapy in the nanotechnology era

2022; Taylor & Francis; Volume: 29; Issue: 1 Linguagem: Inglês

10.1080/10717544.2021.2005719

1521-0464

Yang Yang, Luciana Magalhães Rebêlo Alencar, Martha Sahylí Ortega Pijeira, Beatriz da Silva Batista, Álefe Roger Silva França, Erick Rafael Dias Rates, Ruana Cardoso-Lima, Sara Gemini‐Piperni, Ralph Santos‐Oliveira,

Boron Compounds in Chemistry

The treatment of bone metastatsis as primary bone cancer itself is still a challenge. The use od radium dichloride ([223Ra] RaCl2) has emerged in the last few years as one of the best treatment choice for bone cancer, with especial focus in bone metastasis. The alpha-emitter radiopharmaceutical has showed potent and efficient results in several clinical trials. In this study we have formulated radium dichloride ([223Ra] RaCl2) nanomicelles in order to evaluate and compare with pure radium dichloride ([223Ra] RaCl2). The results showed that nanomicelles at the same dose had a superior effect (20% higher efficient) when compared with pure radium dichloride ([223Ra] RaCl2). The results corroborated the effectiveness of the nanosystem validating the application of nanotechnology in alpha-radiotherapy with radium dichloride ([223Ra] RaCl2).